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They're not just for clots anymore
The identification of the blood-clotting inhibitor, protein S, as a ligand for a
previously 'orphan' family of receptor tyrosine kinases demonstrates a new
role for clotting and anti-clotting proteins in regulating cell proliferation.
The physiological importance of the blood coagulation
system has inspired intense basic and clinical research
interest in its workings. Impaired coagulation in response
to injury leads to bleeding complications - hemophilia
is a classic example. In contrast, impaired ability to regu-
late negatively the clotting response to injury leads to
blood clots that can result in heart attacks, strokes,
phlebitis and pulmonary emboli. For the factors that are
involved in this response, however, this is not the end of
the story. Thrombin, factor X, factor Xa and protein S
have all been shown to modulate inflammation and/or
to be mitogenic. Are we now in a position to integrate
our knowledge of coagulation factors with recent
observations of their involvement in cell activation?
A highly simplified view of the way these factors are
thought to interact to regulate blood coagulation is illus-
trated in Figure 1. Of the interactions shown in Figure 1,
only the binding of factor VIIa to tissue factor has been
demonstrated to elicit cell activation, via the induc-
tion of an intracellular Ca2 + signal [1]. Protein C and
protein S have also been implicated in cell activation, in
addition to their interactions in the coagulation pathway.
Protein C - both before and after activation - can
bind to a newly described protein C receptor expressed
on endothelial cells (Fig. 2). The function of this recep-
tor remains to be determined, but several observations
suggest that it may be involved in inflammation [2].
Firstly, the protein is homologous to the CD1/MHC
class 1 family of proteins, all of which are involved in
inflammation; secondly, protein C has anti-inflammatory
activity in vivo; and finally, receptor synthesis is down-
regulated by the inflammatory cytokine, tumor necrosis
factor (TNF). The recent demonstration that protein S
can bind directly to factor Xa [3] may also further our
understanding of factor Xa/protein S-mediated modula-
tion of cell growth. Furthermore, tissue factor, thrombo-
modulin and binding sites for activated protein C-
protein S complexes are all regulated, either positively or
negatively, on selected cell surfaces by cytokines and
other inflammatory mediators.
Of the various coagulation factors, thrombin, the enzyme
directly responsible for clot formation, has garnered the
most attention as a mediator of cellular responses. Throm-
bin has many activities: it activates platelets, triggers
growth factor synthesis, promotes selected cell prolifera-
tion, causes the synthesis and release of prostaglandin I2,
inhibits neurite outgrowth and is chemotactic for poly-
morphonuclear cells [4]. Most of these functions involve
Fig. 1. During blood coagulation, damage to the vessel surface exposes tissue factor (TF), a regulatory protein, that interacts with factor
Vlla, a protease, to form a physiological activation complex for factor X. Activation of factor X generates the serine protease factor Xa,
which binds to another regulatory protein, factor Va, to form the activation complex responsible for conversion of prothrombin (Pro) to
thrombin (T). Thrombin then binds to thrombomodulin (TM), and this complex converts protein C (PC) to activated protein C (APC).
APC, in turn, interacts with protein S to accelerate the inactivation of factor Va, thus shutting down thrombin generation. Protein C,
protein S, prothrombin and factor X all require vitamin K for biosynthesis of functional proteins, a post translational process that forms
the gamma carboxyglutamic acid residues necessary for Ca2+-dependent membrane binding. Modified from [15].
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Fig. 2. Schematic representation of interactions between coagulation proteins and cell-surface receptors that may be involved in
cellular activation. The coagulation factor-receptor complexes are discussed in the text. EPR1, effector protease receptor 1; EPCR,
endothelial protein C receptor.
the thrombin receptor, a member of the seven transmem-
brane domain family of receptors (Fig. 2). Thrombin
cleaves this receptor, allowing the newly unmasked amino
terminus to serve as a 'tethered' ligand - binding to a
site in the body of the receptor and causing its activation.
Indeed, peptides corresponding to the new amino termi-
nus can activate the intact receptor without requiring
proteolytic processing. Another, structurally similar, pro-
tease-activated receptor has recently been described, but
the physiological activator is unknown [5].
Many of the cells that respond to thrombin are in contact
with blood, at least in injury situations. Other cells bear-
ing the thrombin receptor are unlikely to come directly
into contact with blood, neurons being one example.
One might wonder, therefore, whether thrombin really
plays a role in cellular responses of the nervous system.
The likely involvement of thrombin in this role is sup-
ported by several observations. Firstly, the mRNA
encoding prothrombin is present in astrocytes; secondly,
in the absence of a thrombin inhibitor, the protease
nexin, neurite outgrowth is prevented; and finally, inhi-
bition of thrombin activity by the protease nexin is aug-
mented in a relatively specific fashion by the extracellular
matrix [6]. A role for the thrombin receptor in disease
processes can be inferred from the observations that
thrombin receptor synthesis is induced in vascular
smooth muscle cells after aortic injury (simulating the
process of balloon angioplasty to open diseased coronary
arteries) [7], and that thrombin accumulates in the brains
of Alzheimer's patients, possibly contributing to the
disease process [6].
These observations suggest three features of coagulation
factor-cell interactions. First, the receptors for the coag-
ulation factors may be regulated by exposure of the cells
bearing the receptors to various stimuli, some of which
are not normally in contact with blood. Second, coagu-
lation factors appear to play a role in the regulation of
the proliferative response to vascular injury. Third, coag-
ulation factors may be synthesized at sites other than the
liver, albeit often at low levels. In the absence of the
other regulatory mechanisms that potently control the
function of these proteins in blood, however, even these
low levels may be sufficient to promote extravascular
cellular responses.
Thrombin is not unique in playing roles in inflammation
and cell proliferation. On monocytes, factor X can inter-
act with Macl (CD1 lb/CD18). Macl also interacts with
complement C3bi, fibrinogen, filamentous hemagglu-
tinin from Bordetella pertusis and glycoprotein C expressed
on endothelial cells infected with herpes simplex 1 virus
(Fig. 2) [8,9]. The binding of factor X to Macl appears
to potentiate factor X activation, even in the absence of
the normal cofactor for this process, tissue factor (Fig. 1)
[9]. Factor X and hemagglutinin cross-compete, and
peptides derived from either protein can inhibit endothe-
lial cell transcytosis of leukocytes and partially inhibit loss
of blood-brain barrier function following bacterial chal-
lenge. Furthermore, fibrinogen bound at a different site
to Macl probably plays an important role in the binding
of monocytes to ICAM-1. This facilitates the attachment
and transmigration of monocytes across endothelium.
Once formed, factor Xa on monocytes interacts with a
recently identified receptor, effector protease receptor 1
(Fig. 2), and this interaction appears to work synergisti-
cally with other agonists to promote lymphocyte prolifer-
ative responses [10]. Factor Xa binding to this receptor
can also enhance prothrombin activation, apparently in the
absence of the normal cofactor, factor Va. This pathway
not only facilitates proliferative responses, therefore, but
provides an alternative pathway for thrombin generation.
Although relatively weak compared to the normal coagu-
lation responses, this mechanism could provide an alter-
native prothrombin activation pathway when monocytes
cross the endothelial barrier.
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The notion that factor Xa can influence cell growth is
supported by several additional observations. Factor Xa
stimulates the release of growth factors from endothelium,
particularly platelet-derived growth factor. Factor Xa, fac-
tor X and the anticoagulant protein S can act as mitogens
of smooth muscle cells. Gasic et al. [11] observed that the
proliferative response to these factors was as rapid as that
of a direct mitogen, suggesting that they might trigger the
mitogenic response directly. The receptors involved were
not identified, but it appeared that the requirements for a
mitogenic response to factor Xa and protein S were dis-
tinct from the requirements for such a response to factor
X. The most compelling experiment in this regard was
that two relatively specific protease inhibitors of factor Xa
independently blocked the mitogenic response to factor
Xa, but not factor X. Surprisingly, they also blocked the
response to protein S. As protein S cannot be converted
to a protease, these observations suggest that protein S acts
by stimulating or interacting with a protease, possibly fac-
tor Xa, to produce a mitogenic response. A full under-
standing of the mechanism and potential significance of
these observations, however, required the identification of
the receptor-mediated processes that could link protein S
to a mitogenic response.
Recently, approaching this problem from a totally differ-
ent perspective, Stitt et al. [12] were searching for the
factors that could bind to, and activate, a family of
'orphan' tyrosine kinases, known as Tyro 3, Tyro 7 and
Tyro 12. Their approach involved the examination of
cellular and blood sources for such a factor. As many of
the kinases in this family are found on extravascular cells,
it was surprising that candidate factors were identified in
plasma and endothelial cell-conditioned media. The
identification of these factors was based on their ability to
cause phosphorylation of the kinase and to bind directly
to the kinase. The authors subsequently isolated a factor
from endothelial cell-conditioned media and identified it
as protein S, the negative regulatory protein of coagula-
tion (Figs 1 and 2). Supernatants of transfected COS cells
expressing protein S stimulated both phosphorylation of
Tyro 3 expressed by transfected Rat2 fibroblasts, and
mitogenic responses in transfected cells expressing a
chimeric Tyro 3 receptor composed of the ectodomain
of Tyro 3 and the endodomain of the neurotrophin
receptor, TrkB. Taken together, it appeared that protein S
can induce receptor autophosphorylation, and that this is
a mitogenic stimulus.
Another member of the family, Tyro 7 (Axl), did not
bind protein S; using a similar strategy, the authors iden-
tified endothelium, but not serum, as a source for a Tyro
7 ligand. This factor did not compete with protein S,
and isolation from the conditioned medium of endo-
thelial cells revealed that the protein was probably the
bovine form of Gas 6 - a protein homologous to, but
distinct from, protein S. Gas 6 was originally identified
as a growth-arrest protein, as it was expressed only dur-
ing serum starvation [13]. Gas 6 may play a role in regu-
lating cell proliferation, therefore, by binding to Tyro 7;
however, this possibility was not directly demonstrated in
the study by Stitt et al. [12].
Although most studies on protein S have focused on its
roles in plasma, protein S is synthesized by a number of
extravascular tissues in addition to the liver and endothe-
lium [12,14]. A particularly interesting source of protein S
are Schwann cells in culture, which synthesize significant
amounts of protein S, although in vivo levels of protein S
mRNA in these cells are quite low. Nerve injury, how-
ever, stimulates an increase in protein S mRNA levels.
The combination of the injury-induced expression of
protein S and the ability of protein S to interact with the
Tyro 3/Trk transfected cell line, eliciting a mitogenic
response, suggests that protein S interaction with Tyro 3
may play a role in wound repair.
Taken together, these studies expand our appreciation of
the roles that coagulation/anticoagulation factors may
play in controlling inflammation and promoting cellular
proliferation. Multiple mechanisms are likely to be oper-
ative. Extravascular cells may synthesize these coagula-
tion proteins or their receptors, either constitutively or
in an inducible manner. Alternatively, inflammatory cells
may move from the blood to extravascular tissues, pro-
viding triggers for the activation or synthesis of critical
components of the response.
The exciting observation that protein S can activate Tyro
3 raises many questions. Is a member of the Tyro 3 family
responsible for the ability of factor X, Xa and protein S
to stimulate smooth muscle cell proliferation? If so, how
do factor Xa inhibitors block this process mediated by
the direct binding of protein S to the receptor? If protein
S is the only agonist, how does this lead to receptor
dimerization, or is this unnecessary? Does the ability of
protein C and factor X to bind to protein S provide clues
as to the role of protease inhibitor or the regulation of
receptor activation? A particularly interesting recent
observation is that protein C, like protein S, is synthe-
sized in extravascular tissues and, unlike most coagulation
complexes, protein C and activated protein C interact
with equal affinity with protein S [2].
From an evolutionary point of view, these studies raise
the question of whether the coagulation/anticoagulation
factors arose to control coagulation, or were originally
involved in cellular regulation and were subsequently
adapted to the regulation of the coagulation process.
Alternatively, the control of wound healing, cellular pro-
liferative responses and blood clotting may be much more
intimately linked than is currently envisaged. Of the cel-
lular factors shown in Figure 2, four have been identified
within the last two years. It seems likely that a myriad
new receptors and signal transducing mechanisms, link-
ing coagulation/anticoagulation factors to the regulation
of cellular proliferation and inflammation, will be identi-
fied in the near future. This will provide a more com-
plete picture of this complex process involved in host
defense and tissue repair.
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